Prosecution Insights
Last updated: May 29, 2026

Denali Therapeutics Inc.

10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days

Portfolio Summary

10
Total Pending OAs
8
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

7
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (7)Due ≤ 60 days (1)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
6
Medium (60%)
1
Easy (10%)
3
Unknown (30%)

Rejection Statute Mix

BucketCases
§103 only6 (60%)
Double-patenting only1 (10%)
No statute on record3 (30%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

9
Life Sciences
90% of docket
0
Information Tech
0% of docket
1
Communications
10% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

100 h
Manual time on pending OAs
20 h
Time saved (low, 20%)
35 h
Time saved (mid, 35%)
0.9 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
COLEMAN, BRENDA LIBBY 1 74.7% +15.7%
LIU, XIAO 1 88.7% +11.8%
WHITE, DAWANNA SHAR-DAY 1 62.3% +24.5%
LU, CHENG 1 54.1% +67.9%
COLENA, TRACY CHING-TIAN 1 100.0% +0.0%
ALLEN, MICHAEL D 1 32.6% +48.7%
CHANDRA, GYAN 1 71.1% +27.7%
LIPPERT, JOHN WILLIAM 1 55.7% +42.6%
AEDER, SEAN E 1 56.9% +19.6%
SHUPE, ELIZABETH A 1 63.3% +49.1%

Quick Wins (2)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18701573 MICROGLIAL CELL MORPHOMETRY LIU, XIAO 19d overdue
18248818 METHODS FOR TREATING AND MONITORING FRONTOTEMPORAL DEMENTIA COLENA, TRACY CHING-TIAN 15d overdue

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17178595 ANTI-HER2 POLYPEPTIDES AND METHODS OF USE THEREOF SHUPE, ELIZABETH A 79d overdue
17797644 METHODS FOR THE TREATMENT OF HUNTER SYNDROME CHANDRA, GYAN 37d overdue
18701573 MICROGLIAL CELL MORPHOMETRY LIU, XIAO 19d overdue
18646220 CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE COLEMAN, BRENDA LIBBY 16d overdue
17296506 METHODS FOR TREATING DYSREGULATED LIPID METABOLISM AEDER, SEAN E 15d overdue
17819182 ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS ALLEN, MICHAEL D 8d overdue
18276823 ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF LU, CHENG 46d
17614842 MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT LIPPERT, JOHN WILLIAM 62d

Top Art Units

Art UnitApps
1642 2
1624 1
2664 1
1627 1
1797 1
1671 1
1674 1
1615 1
1643 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18646220 CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE COLEMAN, BRENDA LIBBY 1624 §103 Non-Final OA 16d overdue Pending Apr 25, 2024
18701573 MICROGLIAL CELL MORPHOMETRY LIU, XIAO 2664 §103 Non-Final OA 19d overdue Pending Apr 15, 2024
18288734 METHODS FOR TREATING AND MONITORING PARKINSON'S DISEASE WHITE, DAWANNA SHAR-DAY 1627 DP Non-Final OA 83d Pending Oct 27, 2023
18276823 ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF LU, CHENG 1642 Other Non-Final OA 46d Pending Aug 10, 2023
18248818 METHODS FOR TREATING AND MONITORING FRONTOTEMPORAL DEMENTIA COLENA, TRACY CHING-TIAN 1797 §103 Non-Final OA 15d overdue Pending Apr 12, 2023
17819182 ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS ALLEN, MICHAEL D 1671 §103 Non-Final OA 8d overdue Pending Aug 11, 2022
17797644 METHODS FOR THE TREATMENT OF HUNTER SYNDROME CHANDRA, GYAN 1674 Other Non-Final OA 37d overdue Pending Aug 04, 2022
17614842 MODIFIED RELEASE FORMULATION OF A PYRIMIDINYLAMINO-PYRAZOLE COMPOUND, AND METHODS OF TREATMENT LIPPERT, JOHN WILLIAM 1615 §103 Final Rejection 62d Pending Nov 29, 2021
17296506 METHODS FOR TREATING DYSREGULATED LIPID METABOLISM AEDER, SEAN E 1642 §103 Non-Final OA 15d overdue Pending May 24, 2021
17178595 ANTI-HER2 POLYPEPTIDES AND METHODS OF USE THEREOF SHUPE, ELIZABETH A 1643 Other Final Rejection 79d overdue Pending Feb 18, 2021

Managing Denali Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month